193 related articles for article (PubMed ID: 30350218)
1. Family Spillover Effects in Pediatric Cost-Utility Analyses.
Lavelle TA; D'Cruz BN; Mohit B; Ungar WJ; Prosser LA; Tsiplova K; Vera-Llonch M; Lin PJ
Appl Health Econ Health Policy; 2019 Apr; 17(2):163-174. PubMed ID: 30350218
[TBL] [Abstract][Full Text] [Related]
2. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.
Lin PJ; D'Cruz B; Leech AA; Neumann PJ; Sanon Aigbogun M; Oberdhan D; Lavelle TA
Pharmacoeconomics; 2019 Apr; 37(4):597-608. PubMed ID: 30903567
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.
Lamsal R; Yeh EA; Pullenayegum E; Ungar WJ
Pharmacoeconomics; 2024 Feb; 42(2):199-217. PubMed ID: 37945777
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses.
Lamsal R; Yeh EA; Pullenayegum E; Ungar WJ
Pharmacoeconomics; 2024 May; ():. PubMed ID: 38819718
[TBL] [Abstract][Full Text] [Related]
5. Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US.
Ladapo JA; Neumann PJ; Keren R; Prosser LA
Pharmacoeconomics; 2007; 25(10):817-28. PubMed ID: 17887804
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.
Han R; François C; Toumi M
Appl Health Econ Health Policy; 2021 Jan; 19(1):29-44. PubMed ID: 32661846
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis in spine care: a systematic review.
Kepler CK; Wilkinson SM; Radcliff KE; Vaccaro AR; Anderson DG; Hilibrand AS; Albert TJ; Rihn JA
Spine J; 2012 Aug; 12(8):676-90. PubMed ID: 22784806
[TBL] [Abstract][Full Text] [Related]
8. Considering the societal perspective in economic evaluations: a systematic review in the case of depression.
Duevel JA; Hasemann L; Peña-Longobardo LM; Rodríguez-Sánchez B; Aranda-Reneo I; Oliva-Moreno J; López-Bastida J; Greiner W
Health Econ Rev; 2020 Sep; 10(1):32. PubMed ID: 32964372
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of interventions for medically unexplained symptoms: A systematic review.
Wortman MSH; Lokkerbol J; van der Wouden JC; Visser B; van der Horst HE; Olde Hartman TC
PLoS One; 2018; 13(10):e0205278. PubMed ID: 30321193
[TBL] [Abstract][Full Text] [Related]
10. A scoping review of pediatric economic evaluation 1980-2014: do trends over time reflect changing priorities in evaluation methods and childhood disease?
Sullivan SM; Tsiplova K; Ungar WJ
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):599-607. PubMed ID: 27659998
[TBL] [Abstract][Full Text] [Related]
11. Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.
Yuasa A; Yonemoto N; Kamei K; Murofushi T; LoPresti M; Taneja A; Horgan J; Ikeda S
Adv Ther; 2022 Dec; 39(12):5327-5350. PubMed ID: 36205907
[TBL] [Abstract][Full Text] [Related]
12. Application of classic utilities to published pediatric cost-utility studies.
Finnell SM; Carroll AE; Downs SM
Acad Pediatr; 2012; 12(3):219-28. PubMed ID: 22075466
[TBL] [Abstract][Full Text] [Related]
13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
14. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.
Neumann PJ; Fang CH; Cohen JT
Pharmacoeconomics; 2009; 27(10):861-72. PubMed ID: 19803540
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and quality of pediatric cost-utility analyses.
Kromm SK; Bethell J; Kraglund F; Edwards SA; Laporte A; Coyte PC; Ungar WJ
Qual Life Res; 2012 Oct; 21(8):1315-25. PubMed ID: 22038397
[TBL] [Abstract][Full Text] [Related]
17. Measuring costs in cost-utility analyses. Variations in the literature.
Stone PW; Chapman RH; Sandberg EA; Liljas B; Neumann PJ
Int J Technol Assess Health Care; 2000; 16(1):111-24. PubMed ID: 10815358
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
19. Growth and quality of the cost-utility literature, 1976-2001.
Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of oral health interventions: A systematic review of cost-utility analyses.
Hettiarachchi RM; Kularatna S; Downes MJ; Byrnes J; Kroon J; Lalloo R; Johnson NW; Scuffham PA
Community Dent Oral Epidemiol; 2018 Apr; 46(2):118-124. PubMed ID: 28925508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
